Acasunlimab
Based on 1 publication(s) in Google Scholar
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: ≥99.0%
- CAS. Nr.: 2253937-12-9
- Molecular Weight:143.86 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Acasunlimab
More
Biologische Aktivität
Beschreibung
Isotype
Ig(G1-kappa_G1-lambda2)
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TNFRSF9 & CD274
In Vitro
Acasunlimab (GEN1046; 0.001-1 μM; 0-525 min) promotes interactions between dendritic cells and T cells and enhances T-cell activation[1].
Acasunlimab (0.001-1 μM; 48 h; PD-L1+ Tumor Cells) induces dose-dependent, conditional T-cell proliferation and cytokine production and enhances antigen-specific T-cell–mediated cytotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Double knock-in (dKI) transgenic C57BL/6 mice[1]
-
Dosage:5 mg/kg
-
Administration:Intravenous injection; twice weekly for three cycles
-
Result:Had antitumor activity in double knock-in (dKI) transgenic C57BL/6 mice.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Ig(G1-kappa_G1-lambda2)
.png)
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human 4-1BB/CD137 Protein (ECD, His Tag) can bind Acasunlimab. The EC50 for this effect is 5.74 ng/mL. -
Immobilized Human PD-L1/B7-H1 Protein (ECD) can bind Acasunlimab. The EC50 for this effect is 11.27 ng/mL.
Chemical Information
-
CAS. Nr. 2253937-12-9
-
Appearance Liquid
-
Molecular Weight 143.86 kDa
-
Color Colorless to light yellow
-
SMILES
[Acasunlimab]
-
Synonyms
GEN1046
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Reinheit & Dokumentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Muik A, et, al. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discov. 2022 May 2;12(5):1248-1265. [Content Brief]
[2]. Gao Y, et, al. Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. FEBS Open Bio. 2022 Dec;12(12):2166-2178. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Acasunlimab Related Classifications
HY-P99419 Related Classifications
Powered by Bioz